US CBO says orphan drug exmption could add $6 billion more to cost of ’Big Beautiful Bill’

The US Congressional Budget Office (CBO) has raised concerns that the orphan drug exemption could increase the costs of the proposed 'Big Beautiful Bill' by an additional $6 billion. This revelation is significant as it highlights the potential financial implications of healthcare policies, which could affect funding for other essential services. The debate around drug pricing and healthcare reform continues to be a hot topic, making this development particularly relevant for policymakers and the public alike.